Edik M. Blais
Affiliations: | University of Virginia, Charlottesville, VA |
Area:
Computational Systems Biology, Biomedical Engineering, Cancer MetabolismWebsite:
www.bme.virginia.edu/csbl/Google:
"Edik Blais"Parents
Sign in to add mentor| Shahram Vaezy | research assistant | University of Washington | |
| Donner F. Babcock | research assistant | 2009-2010 | University of Washington |
| Bertil Hille | research assistant | 2009-2010 | University of Washington |
| Jason A. Papin | grad student | 2010- | UVA |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jiang H, Torphy RJ, Steiger K, et al. (2020) Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. The Journal of Clinical Investigation |
| Lowder CY, Dhir T, Goetz AB, et al. (2020) A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience. Surgical Oncology. 33: 118-125 |
| Pishvaian MJ, Blais EM, Brody JR, et al. (2020) Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. The Lancet. Oncology |
| McGrath JS, Honrado C, Moore JH, et al. (2020) Electrophysiology-based stratification of pancreatic tumorigenicity by label-free single-cell impedance cytometry. Analytica Chimica Acta. 1101: 90-98 |
| Hendifar AE, Blais EM, Ng C, et al. (2020) Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies. Journal of Clinical Oncology. 38: 4641-4641 |
| Gong J, Blais EM, Bender JR, et al. (2019) Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. Oncotarget. 10: 6260-6268 |
| Rawls KD, Blais EM, Dougherty BV, et al. (2019) Genome-Scale Characterization of Toxicity-Induced Metabolic Alterations in Primary Hepatocytes. Toxicological Sciences : An Official Journal of the Society of Toxicology |
| Guan M, Gong J, Hendifar AE, et al. (2019) Multiplatform profiling of pancreatic neuroendocrine tumors (PanNETs) identifies novel co-occurring pathogenic alterations and associations with clinicopathologic factors. Journal of Clinical Oncology. 37: 211-211 |
| Petricoin E, Barg D, de Arbeloa PM, et al. (2019) Visualizing real-world outcomes through the lens of a molecular tumor board: Persona-typing pancreatic cancers for clinical decision support. Journal of Clinical Oncology. 37: e18100-e18100 |
| Pishvaian MJ, Blais EM, DeArbeloa P, et al. (2019) Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx). Journal of Clinical Oncology. 37: 4138-4138 |